An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant.

Prevymis (letermovir) - Merck (MSD)

http://www.ncbi.nlm.nih.gov/pubmed/41321117

Barbara Haber; Christopher L Gilbert; Cyrus Badshah; Eleni Tholouli; Ella J Ariza-Heredia; Genovefa A Papanicolaou; Michele I Morris; Natalya Broyde; Patrizia Chiusolo; Sanjeet S Dadwal

Dec 1, 2025